文献速递骨质疏松与代谢性骨病

抗骨质疏松药物使用:过少、过多还是恰好?挪威HUNT研究

Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway.
PubMed 文献 · Osteoporos Int · 2018-05-17

基于挪威HUNT3研究(2006-2008年)15,075名女性和13,386名男性(50-85岁)及挪威处方数据库,分析抗骨质疏松药物(AODs)使用情况。在FRAX主要骨质疏松性骨折(MOF)评分≥20%者中,25%女性和17%男性接受AODs治疗;而FRAX MOF<20%者中仅3%女性和1%男性治疗。作者认为高危骨折风险人群存在治疗不足。

要点

  • FRAX MOF≥20%者中25%女性和17%男性接受AODs,FRAX MOF<20%者中仅3%女性和1%接受治疗。
  • 女性中高龄是治疗最强预测因素(HR 3.84,95%CI 2.81-5.24),男性中糖皮质激素使用是最强预测因素(HR 5.28,95%CI 2.70-10.35)。
  • 骨密度亚组中T值≤-2.5是最强预测因素(女性HR 3.98,95%CI 2.67-5.89;男性HR 13.31,95%CI 6.17-28.74)。

核心结论

  • 本研究提示骨折高风险个体中存在抗骨质疏松药物治疗不足。

研究设计与样本

  • 数据来自2006-2008年开展的Nord-Trøndelag健康研究(HUNT3)和挪威处方数据库,纳入15,075名女性和13,386名男性,年龄50-85岁。
  • 在4538名女性和2322名男性亚组中测量股骨颈骨密度(BMD)。
  • 采用Cox比例风险模型估计HUNT3后2年内新发使用AODs的预测因素风险比(HR)。

主要发现

  • FRAX MOF≥20%者中,25%女性和17%男性接受AODs治疗;FRAX MOF<20%者中,3%女性和1%接受治疗。
  • BMD亚组中,骨折高风险者24%女性和16%男性接受治疗,而未满足标准者中女性和男性分别为3%和1%。
  • 女性中治疗最强预测因素为高龄(HR 3.84,95%CI 2.81-5.24),其次为糖皮质激素使用(HR 2.68,95%CI 1.84-3.89)。
  • 男性中预测因素为糖皮质激素使用(HR 5.28,95%CI 2.70-10.35),其次为多病共存(HR 3.16,95%CI 1.31-7.63)。
  • BMD亚组中T值≤-2.5是最强预测因素(女性HR 3.98,95%CI 2.67-5.89;男性HR 13.31,95%CI 6.17-28.74)。

关键数值与推荐

  • 高风险定义为FRAX主要骨质疏松性骨折(MOF)评分≥20%;BMD亚组中额外定义为FRAX MOF≥20%或T值≤-2.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Use of anti-osteoporotic drugs (AODs) was examined in a Norwegian population 50-85 years. Among them with Fracture Risk Assessment Tool (FRAX) score for major osteoporotic fracture ≥ 20, 25% of the women and 17% of the men received AODs. The strongest predictors for AODs were high age in women and use of glucocorticoids among men. INTRODUCTION: To examine the use of anti-osteoporotic drugs (AODs) and to identify predictors for prescriptions. METHODS: Data were obtained from the Nord-Trøndelag Health Study (HUNT3) performed in 2006-2008 and the Norwegian Prescription Database, including 15,075 women and 13,386 men aged 50-85 years. Bone mineral density (BMD) in the femoral neck was measured in a subgroup of 4538 women and 2322 men. High fracture risk was defined as a FRAX score for major osteoporotic fracture (MOF) ≥ 20%; in the subgroup with BMD, high risk was in addition defined as FRAXMOF ≥ 20% or T-score ≤ - 2.5. Hazard ratios (HRs) for predictors of incident use of AODs within 2 years after HUNT3 were estimated by Cox' proportional hazards model. RESULTS: Among individuals with FRAX MOF ≥ 20%, 25% of the women and 17% of the men were treated with AODs. Among those with FRAX MOF < 20%, 3% and 1% were treated, respectively. In the subgroup with BMD measurement, 24% of the women and 16% of the men at high risk of fractures were treated, compared to 3 and 1% in women and men not fulfilling the criteria. In women, high age was the strongest predictor for treatment (HR 3.84: 95% confidence interval 2.81-5.24), followed by use of glucocorticoids (GCs) (2.68:1.84-3.89). In men, predictors were use of GCs (5.28: 2.70-10.35) followed by multimorbidity (3.16:1.31-7.63). In the subgroup with BMD, T-score ≤ - 2.5 was the strongest predictor (women 3.98:2.67-5.89; men 13.31:6.17-28.74). CONCLUSIONS: This study suggests an undertreatment of AODs in individuals at high risk of fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hoff M, Skurtveit S, Meyer HE, et al. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. Osteoporos Int. 2018. PMID: 29774403. doi:10.1007/s00198-018-4560-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。